Navigation Links
Early Estrogen Therapy May Reduce Cardiovascular Risks

A new analysis of both estrogen and estrogen plus progestin shows a 24 percent reduction in risk for coronary heart disease events in women starting// hormone therapy less than 10 years after menopause.

The analysis, by researchers at Yale and eight other study centers participating in the Kronos Early Estrogen Prevention Study (KEEPS), also showed a 30 percent reduction in overall deaths among women aged 50 to 59 using hormone therapy.

However, the new study, “Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause,” also found that hormone therapy increased coronary heart disease events by 28 percent in older women, and that deaths increased by 14 percent in women aged 70 to 79. There was a slightly elevated risk of stroke at all ages studied.

The Women’s Health Initiative was halted in July 2002 due to overall elevated risks. This new analysis indicates that excess cardiovascular risk is confined to older women, which is consistent with previous research. Prior to the WHI, most data suggested that hormone therapy was associated with a high degree of protection (30 to 50 percent reductions) against coronary heart disease, all-cause mortality, and osteoporotic fractures, in addition to a small increase in breast cancer risk.

“This new analysis of WHI data seems to confirm earlier findings that estrogen may be good early, but bad late,” said Dr. S. Mitchell Harman, director of the Kronos Longevity Research Institute. The Institute is conducting the KEEPS, a randomized, controlled, double-blinded trial of 720 women designed to provide prospective data on the risks and benefits of early menopausal hormone therapy, particularly as it relates to the progression of atherosclerosis.

“In this study, hormone therapy reduced overall mortality in the younger menopausal women,” said lead investigator of the KEEPS trial at Yale, Hugh S. Taylor, M.D., associate professor in t he Departments of Obstetrics, Gynecology & Reproductive Sciences and Molecular Cellular & Developmental Biology. “It is important not to trivialize quality of life. No one should tell women to put up with hot flashes to avoid serious risk, if in reality this therapy saves lives.”

The KEEPS will also examine whether the natural human estrogen, estradiol, delivered through the skin via a patch is equally effective as, and potentially safer than, oral estrogen. Researchers have speculated that this method may be safer since transdermal estrogen does not go to the liver in high concentrations and has been shown to have little or no effect on clotting disease.

“The WHI was instrumental in providing a roadmap for the next phase of research to examine whether estrogen protects younger women from cardiovascular disease, as earlier observational studies indicated, said Harman. “KEEPS is designed to provide useful new data to begin answering women’s questions and help shape future research.”

Source-YALE Universty
SRM/B
'"/>




Related medicine news :

1. Early detection of prostate cancer
2. Early detection of heart attack
3. Early puberty linked to nutrition
4. Early Clue to Down Syndrome
5. Early delivery can prevent cancer
6. Early puberty more resistance
7. Early menopause- The cause
8. Early menopause- The cause
9. Early Warning System For Breast Cancer
10. Early therapy aids eyesight
11. Early detection of colorectal cancer may be hindered by coloured toilet disinfectants
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... ... December 05, 2016 , ... BSI and Brenntag Canada have been appointed ... for distribution of their natural fruits and beverage colorants effective November 1, ... addition to our Life Sciences product portfolio,” said Steve Brauer, President of Brenntag Specialties, ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... Point Partners ("GPP") portfolio company, today announced it has acquired the assets ... TCS was previously a subsidiary of Chiltern International and focuses on clinical ...
(Date:12/5/2016)... IL (PRWEB) , ... December 05, 2016 , ... The ... to the individual looking to buy neoprene knee sleeves for lifting and ... The design focuses heavily on two main aspects to provide a higher quality knee ...
(Date:12/5/2016)... ... December 05, 2016 , ... A ... Patch® significantly improves the reproducibility and accuracy of placing precordial electrodes with little ... , Over the last 60 years, studies have shown that single electrode misplacement ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging ... Anti-Aging Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec 5, 2016 Research ... Market by Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, Disease ... - Global Forecasts to 2021" report to their offering. ... , , ... USD 730.7 Million in 2021 from USD 574.8 Million in 2016, ...
(Date:12/5/2016)...   BIOTRONIK today announced the first patients ... the safety and feasibility of performing the minimally invasive ... BioMonitor 2 is an insertable cardiac remote monitor ... a patient,s skin to help physicians accurately detect and ... a leading cause of stroke and heart failure. BioMonitor ...
(Date:12/5/2016)... Dec. 5, 2016  CVS Health, the nation,s largest ... a perfect score of 100 percent on the Corporate ... CEI is an annual national benchmarking survey and report ... administered by the Human Rights Campaign Foundation. ... that our colleagues, customers and suppliers bring to CVS ...
Breaking Medicine Technology: